乳癌組織抽出液および血清ErbB-2蛋白測定の腫瘍マーカーとしての有用性

• 菅野 康吉

  栃木県立がんセンター研究所がん遺伝子研究室 国立がんセンター中央病院臨床検査部

• 牛尼 美年子

  国立がんセンター中央病院臨床検査部

• 福富 隆志

  国立がんセンター中央病院外科

• 津田 均

  国立がんセンター研究所病理部

• 木藤 孝

  ニチレイ診断薬事業部

• 大倉 久直

  茨城県立中央病院・茨城県立地域がんセンター

書誌事項

タイトル別名

• Combined Measurement of the c-erbB-2 Protein in Breast Carcinoma Tissues and Sera is Useful as a Sensitive Tumor Marker for Monitoring Tumor Relapse.

抄録

c-erbB-2 protein levels in tissue extracts and sera were determined in158 patients with breast carcinoma by a sandwich enzyme immunometric assay (EIA) using monoclonal antibodies directed to the extracellular domain of the c-erbB-2 oncogene protein (ErbB-2). In an analysis of tissue extracts, 48 samples (30.3%) showed ErbB-2 levels exceeding 18.0 ng/mg protein (group A), while in 110 samples these levels were below 18.0 ng/mg protein (group B). The level of ErbB-2 in tissue extracts was significantly associated with immunohistochemistry and ErbB-2 levels in preoperative sera. During follow-up, 48 patients (30.3%) developed recurrent disease: 17 in group A (35.4%) and 31 in group B (28.2%). The sensitivity of serum ErbB-2 in patients with relapsed breast cancer was 84.6% (11/13) in group A and 43.5% (10/23) in group B. In an analysis of serum samples taken before relapse, 90.9% (10/11)of the subjects in group A and 26.7% (4/15) of those in group B were shown to be positive for serum ErbB-2. Serum ErbB-2 in group A was a more sensitive marker than other tumor markers such as CEA, CA15-3 and NCC-ST-439. Thus, the determination of ErbB-2 in tissue extracts of breast carcinoma may be useful for assessing c-erbB-2 protein expression in the primary tissue, and indicates that serum ErbB-2 may be a sensitive marker for monitoring tumor relapse.

収録刊行物

• 日本分子腫瘍マーカー研究会誌

  日本分子腫瘍マーカー研究会誌 16 8-9, 2001

  日本分子腫瘍マーカー研究会

キーワード

• c-erbB-2
• Her2
• 乳がん

詳細情報

• CRID: 1390001205112363520
• NII論文ID: 130004927534
• DOI: 10.11241/jsmtmr.16.8
• ISSN: 24338575
• 本文言語コード: ja
• データソース種別:
  • JaLC
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可